KYPROLIS 60 MG VIAL
Order with delivery in a thermo-refrigerator to Worldwide. The price is indicated above. Without recipe! Attached are instructions for use and a quality certificate from the manufacturer.
Our product is manufactured in accordance with the requirements of the European GMP EU and German Section 13 AMG laws guaranteeing the quality and safety of the medicine.
Kyprolis is an antitumor drug, a selective proteasome inhibitor. The description is based on instructions for use, patient reviews and the results of clinical trials.
On July 27, 2012, the drug was approved by the Food and Drug Administration (FDA) as a monotherapy for patients with multiple myeloma.
It can be used in combination with Revlimid (lenalidomide) and Dexamethasone , which you can also buy.
Clinical Trials of Kyprolis
The first study examined the effectiveness of Kiprolis as a means of monotherapy for recurrent multiple myeloma.
Results: 36% of patients received a clinical response, 23% of patients experienced persistent improvement, and the average remission time was 7.8 months. As a result, the drug was approved for use by the FDA.
Further, multiple studies of the effectiveness and safety of the drug as a therapy in patients with recurrent and refractory multiple myeloma were conducted. Kyprolis was prescribed in the regimen with lenalidomide and dexamethasone.
Results: 100% of patients received a partial clinical response, of which almost 70% further received persistent improvement.
Carfilzomib regimen with lenalidomide and dexamethasone has shown efficacy and relatively good tolerance over a long course of therapy.
Side effects: thrombocytopenia, anemia, lymphopenia, neutropenia, pneumonia, fatigue and hyponatremia.
Phase III clinical trials evaluated the efficacy of a combination of carfilzomib, lenolidamide, and dexamethasone in patients with newly recurring multiple myeloma. The results showed that the regimen of the three drugs was much more effective than the combination of lenolidamide and dexamethasone.
How does Kyprolis work
Karfilzomib selectively binds to specific protein complexes in tumor cells – proteasomes. Blocking their functions leads to disruption of cancer cell division processes, which initiates apoptosis (cell death). Due to this, the growth of cancer is suppressed.